News | February 25, 2026
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Nadda underlined that India’s policy framework is aligned with this transformation
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Subscribe To Our Newsletter & Stay Updated
